The partnership will provide plan members with access to digital services aimed at older patients.
Stock.adobe.com
DarioHealth Corp signed a new contract with a national Medicare Advantage health plan. Dario is global digital health market company, and this contract will allow both companies to provide Plan members with Dario’s behavioral health solution, Twill. According to a press release, Dario was selected because its AI-based network has the opportunity to provide elder plan members with access to digital tools that will address broad emotional health and well-being services.
In a press release, Dario’s chief commercial officer Steven Nelson said, “There is a misconception that seniors will not engage with digital health, but our data tells us that is just a myth. Pre-Twill, the senior population on the Dario's platform was roughly 30%, a number that will expand with this partnership. The high comorbidity rate between metabolic and mental health conditions is something that Dario is prepared to address upon expansion of this partnership down the road. Seniors will engage with solutions that are tailored and relevant to their unique needs, and we've proven this across behavioral health and chronic health needs. We are excited about the momentum of our B2B2C core channel to health plans and employers."
Nelson continued, "The addition of another national health plan to our client base provides significant opportunity for revenue expansion and allows us to implement our newly refined enrollment and engagement technologies into a wider population of members. We believe that our comprehensive product offering not only helps secure more revenue from new clients but also generates additional revenues from existing clients by exposing them to additional products or larger populations. The B2B2C channel is contributing more than 70% of our revenues as of the first quarter of 2024, and we expect it to continue growing as a result of such contracts."
This is Dario’s latest announcement for Twill. In September, the company announced that it had integrated Twill with cardiometabolic health solutions.2
In a press release issued at the time, Dario’s chief product officer Keren Zimmerman said, “There is no single standard of care for every chronic health condition that will work across the diversity of members on Dario's platform. That's why we are constantly assessing clinical evidence and behavioral engagement data to continuously enhance the way we support our members. The new enhancements provide an element that many people need in order to achieve better results. Integrating these capabilities into the Dario platform is just the first step in driving a deeper, more effective approach to health management as we aim to build out the market's most holistic, consumer-centric digital health platform.”
In the same press release, Nelson added, “One common theme we hear in the market is the need for better adoption of digital health. We believe that our ability to leverage unique social and community capabilities from Twill by Dario will assist us in creating one of the most comprehensive engagement platforms in the market. Combined with our proven approach to chronic condition management, we believe that we are able to offer an unparalleled ability to engage the right members at the right time for maximum, sustainable impact.”
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.